Tender Details

Country: USA
Summary: Pluvicto and Lutathera | VA GLA
UST Ref No: 123991909
Deadline: 15 Aug 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 36C26225Q1321
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
NOTICE OF INTENT TO SOLE SOURCE
This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government-s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.
The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML and LUTATHERA LUTETIUM LU 177 DOTATATE in quantities listed below:
NDC#
Contract
Description
Qty
UOM
69488-0010-61
36F79720D0180
PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML
105
EA
69488-0003-01
36F79720D0180
LUTATHERA LUTETIUM LU 177 DOTATATE
10
EA

VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy. Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180.
This notice of intent is neither a formal sol...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Pluvicto and Lutathera | VA GLA - USA Tender

The VETERANS AFFAIRS, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Pluvicto and Lutathera | VA GLA. This tender is published on USARFP under UST Ref No: 123991909 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-08-15.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.